The Private Equity ‘Wall Of Money’

Luke Cummings

A recent market report from Pitcher Partners found that M & A activity in 2017 increased 55% compared with the prior year, with numerous industry players such as Morgan Stanley, KPMG, and more all suggesting that M & A activity is showing no signs of slowing down just shy of... Show More

Are Investors Missing Out On The M&A Boom?

Luke Cummings

A recent article from Tony Boyd in the Australian Financial Review shone a light on just how active the domestic Australian market has been for M & A activity in 2018. Our last Livewire submission seven months ago touched on a few key things to look out for when trading... Show More

Why we see another 3-4% upside & where to invest now

James Gerrish

Last week was a fascinating one in equity land with MM again becoming bullish the local ASX200 targeting the 6200-6250 area, now only around 3% higher. It was refreshing to see local stocks, even in the face of the Hayne royal commission, sit in the winners cycle of global indices... Show More


What Mattered Today; UBS reignite the bank sell off

James Gerrish

After yesterday’s day off the market was choppy through the morning before selling kicked in - particularly in the banks today. Westpac in particular was sold off hard as UBS heavily reduced their target price and outlook for the bank – more on this later. Healthcare got a boost with... Show More


Make market corrections your ally

Roger Montgomery

Recent experience excepted, corrections are typically more frequent and regular than many would prefer, so investing should not occur without acceptance of this. That said, it’s important to prepare, first by making the right investments, and secondly by adopting the right temperament. Show More


Join the conversation

An investor's guide to artificial intelligence (AI)

Livewire Exclusive

At Livewire’s 2017 investor forum, artificial intelligence (AI) was pegged as the #1 theme that investors need to be aware of. We're already seeing the impacts in our day to day lives and the influence of AI is set to change whole industries and the jobs associated with them. Show More

See 1 more comment

Takeaways from Healthscope's investor day

Morgans Financial Limited

Senior Analyst Derek Jellinek attended the Healthscope investor day earlier this week. Below are his comments as made in a Morgans presentation afterwards. Transcription follows, with full video below: Show More

healthcare morgans life sciences healthscope ASX:HSO

Healthcare sector update

Morgans Financial Limited

Scott Power and Derek Jellinek discuss CSL Limited, Healthscope, Ramsay Health Care, ResMed, Sirtex Medical, Nanosonics, and Ansell following reporting season. Transcript, podcast and video below. Show More


The best and worst of reporting season

Livewire Exclusive

Catherine Allfrey from Wavestone Capital and Chad Slater from Morphic Asset Management highlight the best and worst from reporting season, including one company that Morphic has been openly short on, but has revised its view post-reporting season, saying: “My god, it was a good result.” Show More


Healthscope shares are too cheap

Morgans Financial Limited

FY17 underlying results were below expectations, weighed down by continued soft conditions, cost pressures and volatile case mix in the core Hospital division. 
Increased competition and ramping VIC greenfields further pressured Hospital earnings, pushing it below expectations and guidance, and offsetting strong above market gains from brownfields, which remain on... Show More


Can Healthscope climb out of the sin bin?

Livewire Equities

When it re-listed in July 2014 Healthscope was the largest IPO to hit the ASX in four years. Having spent time held by private equity, the $3.6 billion float was priced on a 22x PE. It's been a bumpy ride, but opinions on the outlook are divided ahead of today's... Show More

healthscope ASX:HSO

Morgans reporting season candidates for surprise or disappointment

Andrew Tang

FY17 reporting season kicks off in earnest mid-August and according to the latest IBES consensus earnings estimates, EPS growth for the S&P/ASX200 is forecast at 13% in FY17, slightly down from 13.6% at the end of 1H17. Pleasingly this would still mark the end of the earnings recession after two... Show More

3 stocks in the firing line

James Gerrish

As we consider different areas to allocate funds into the current market weakness potential tax loss selling should definitely be considered as June slowly evolves. The ASX200 is up almost 6% for the calendar year hence there will not be the number of candidates which would typically be available in... Show More

Is Healthscope the last buying opportunity left in healthcare stocks?

Michael Gable

We have been bearish on Healthscope (HSO) for a while. Having fallen quite a bit in the last year, especially compared to other healthcare stocks, is it now time to jump in? Here we analyse the stock's fundamentals and also how it is looking on the chart. Show More


Join the conversation

Sunset Strip > Trading Day Wrap From Blue Ocean 20170601

Mathan Somasundaram

Local market flip-flopped to finish as a positive day despite weaker China data. Tax loss selling in June will add to the seasonal weakness while better than expected retail data was mixed with weaker than expected China data. Market was buying into safety and weak currency stocks today. The best... Show More

8 stocks on our BUY list

James Gerrish

The market sell-off which we have been waiting for continued yesterday, with the ASX200 testing the psychological 5700 support mid-morning, before staging an encouraging 40-point (0.7%) rally into the close. The selling was pretty broad based although the resources and telco’s did perform well with OZ Minerals (OZL), RIO Tinto... Show More

5 top wires last month

Alex Cowie

In case reporting season kept you busy, we've summarised five top wires in February for you. Peter Quinton’s top ten picks for 2017, our fund manager earnings results review, and Buy Hold Sell with ‘Quality stocks on sale’ all deliver useful stock ideas. On big picture thinking, we bring you... Show More

Healthscope remains a core holding

Morgans Financial Limited

Healthscope's FY17-19 underlying earnings increase by 6.5%, but are offset by higher D&A and interest. With underlying earnings ticking higher and shares trading at a discount to RHC, we continue to view HSO as a core portfolio holding and maintain our Add rating. Show More


Coca Cola Amatil, Stockland, QUBE Holdings, Healthscope and Fairfax Media - First Impressions from Reporting.

Bell Potter

Coca Cola Amatil (CCL): Divisional highlights:Australia Beverage volumes down 2.1%. EBIT down 1.8% to $455.3m, EBIT margin up 0.3ppts to 17.1%; NZ & Fiji volumes up 9.6%. EBIT up 6.9% to $105.6, EBIT margin down 02ppts to 19.1%; Indonesia and PNG volumes up 6.2%. EBIT up 42.9% to $69.6m, EBIT... Show More

ASX:CCL ASX:FXJ ASX:QUB ASX:SGP Longform ASX:HSO February 2017 Reporting Season

Hyperion: There’s a real opportunity at the moment

Livewire Exclusive

Tim Samway, Managing Director at Hyperion Asset Management, says that a focus on macro themes has created a real opportunity in a number of high-quality companies. “It’s very easy to take your eye off the ball, and that is the bottom-up approach of which companies are doing well over the... Show More


Join the conversation